Praxis Precision Medicines (PRAX) on Monday filed a registration statement with the US Securities and Exchange Commission for the potential sale of securities from time to time in one or more offerings.
The filing covers, common stock, preferred stock, debt securities, warrants and units.
The company also filed a supplement prospectus for the offer and sale of common stock up to $250 million under an open market sale agreement.
The company plans to use the net proceeds to fund research, develop product candidates, for working capital and other general corporate purposes.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.